CSChristopher M. Saddler

Christopher M. Saddler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher M. Saddler has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Real World Utilization of Protocolized T‐Cell Immunity Panel Screening in Cytomegalovirus Seropositive Kidney Transplant Recipients

    by Hanna Kleiboeker, Cassilyn Streblow, Jillian Descourouez, Christopher Saddler, John Rice, Didier Mandelbrot, Jon Odorico, Margaret Jorgenson

    Background: Recently updated guidelines suggest monthly cytomegalovirus (CMV) cell‐mediated immunity (CMI) testing in seropositive (R+) kidney transplant recipients to stratify posttransplant CMV risk and guide prophylaxis. UW Health has protocolized T‐cell immunity panel (TCIP) testing since 2023. The purpose was to assess real‐world implementation of TCIP testing and the feasibility of this approach. Methods: This retrospective cohort study included adult R+ renal transplant (RTX) recipients transplanted March 1, 2023, to April 9, 2025, received lymphocyte depleting induction and completed TCIP testing at 3 months posttransplant. Results: Here, 234 patients were eligible for protocolized TCIP testing during the study period, with 160 patients obtaining a TCIP (68.4%). Mean time to TCIP draw was 94 ± 15.6 days post‐RTX. Of those who obtained TCIP, 75 had positive, 57 negative, and 28 with indeterminate results. Significantly more patients with indeterminate TCIP received alemtuzumab induction (8.0% vs. 8.8%vs. 89.3%, p < 0.0001). Positive TCIP facilitated significantly shorter prophylaxis duration (153.8 vs. 172.2 vs. 180.1 days, p = 0.003). WBC were significantly lower among patients with an indeterminate TCIP (6.3 vs. 6.1 vs. 4.4 × 10 3 cells/mm 3 , p = 0.0006). Patients with indeterminate TCIP were more likely to have ALC ≤ 400 cells/µL (32.0% vs. 33.3% vs. 89.3%, p < 0.0001). Incidence of post‐prophylaxis CMV infection was comparable. Conclusion: In this study, implementing protocolized TCIP testing at 3 months posttransplant in R+ kidney transplant recipients was feasible, with the main limitation being lab related draw‐time considerations. Based on our center specific experience, stratification based on patient‐specific factors should be considered before widespread implementation to optimize evaluable results given cost burden associated with testing.


  • Open Access

    Landscape of Current Transplant Infectious Disease Training Programs

    by Michael J. Scolarici, Jessica Tischendorf, Rachel Filipiak, Lara Danziger‐Isakov, Benjamin Hanisch, Alice Sato, Saman Nematollahi, Christopher Saddler

    Background: Transplant infectious disease (TID) training is not accredited by the Accreditation Council for Graduate Medical Education (ACGME) and is not standardized. Prior surveys of the training landscape in TID have focused on fellow responses; we sought description of programs from program directors and coordinators. Methods: Along with the American Society of Transplantation (AST) Infectious Disease Community of Practice (IDCOP), we administered a survey to adult and pediatric ID training programs focusing on the structure, funding, curriculum, and outcomes of ID fellows participating in TID fellowships and tracks. This manuscript is a work product of the American Society of Transplantation's Education Committee. Results: We had 42 respondents representing 15 adult TID fellowships, 12 adult TID tracks, 4 pediatric TID fellowships, and 6 pediatric TID tracks. Adult TID fellowships required slightly more inpatient weeks than adult TID tracks: 26 versus 24 ( p = 0.03). A majority of adult TID fellowships 10/14 (71%) rely on multiple sources of funding for their programs. A total of 67% of adult and 75% of pediatric TID fellowships have didactic curriculum, distinct from their general fellowship, and 53% of adult TID fellowships and no pediatric TID fellowships have distinct core competencies to evaluate TID fellows. Most TID fellows are pursuing TID‐focused clinical careers. Conclusions: Substantial heterogeneity exists among TID fellowships, and between fellowships and tracks. Future directions include updating prior guidance for adult and pediatric TID tracks and fellowships on curriculum, core competencies, and baseline requirements to ensure adequate competency in the care of these vulnerable patients.


  • Open Access

    Infective endocarditis is rare in patients with hematologic malignancy and neutropenia

    by Michael J. Scolarici, Leigh R. Berman, Natalie Callander, Jeannina Smith, Christopher Saddler

    Background: Infective endocarditis (IE) is a serious complication of bloodstream infections (BSIs) that occurs at variable rates depending on the pathogen and clinical setting. There is a paucity of data describing the risk of IE in patients with hematologic malignancy who develop bacteremia while neutropenic.Methods: Adult patients on the hematology ward from January 2018 to December 2020 with hematologic malignancy and bacteremia were evaluated retrospectively for endocarditis by applying the 2023 Duke‐ISCVID criteria. Charts of possible cases were evaluated 90 days after the initial BSI for new infectious complications that could indicate missed IE. Descriptive statistics compared patients admitted for hematopoietic stem cell transplantation (HSCT) to those admitted for alternative reasons (non‐HSCT).Results: Among the 1005 positive blood cultures initially identified, there were 66 episodes in 65 patients with hematologic malignancy and at least grade 3 neutropenia for a mean duration of 11.4 days during their admission. Transthoracic echocardiography (TTE) was performed in 34.8% of BSIs, and transesophageal echocardiography (TEE) in 6.1%. There were no new infectious complications in possible cases 90 days after their initial BSI. No cases of endocarditis were identified.Conclusions: Endocarditis is rare amongst patients with hematologic malignancy, bacteremia, and neutropenia, and no cases were identified in this cohort. The use of routine TTE in this setting seems unwarranted, and the addition of TEE is unlikely to improve patient‐centered outcomes. image


  • Risk factors for high level cytomegalovirus viremia in liver transplant recipients and associated outcomes

    by Hanna L. Kleiboeker, Margaret R. Jorgenson, Glen E. Leverson, John P. Rice, Christopher M. Saddler, Jeannina A. Smith, David Al‐Adra

    Purpose: To evaluate epidemiology, risk‐factors, and outcomes of high‐level (HL) cytomegalovirus (CMV) viremia in liver transplant recipients.Methods: Adult patients receiving a liver transplant between 1/1/2017 and 9/30/2020 were evaluated. Viral loads at University of Wisconsin Health Clinical Laboratories were required to allow for numerical comparison. Primary objective was incidence and outcomes of HL CMV viremia (viral‐load > 100 000 IU/ml). Secondary objective was to elucidate risk factors to allow targeted interventions.Results: Two hundred nine patients met inclusion criteria; 175 kept their graft for at least 240 days. Of these nine patients developed HL CMV, 28 developed low‐level (LL CMV, viral‐load 250–100 000 IU/ml), and 138 did not develop CMV viremia. When comparing these three groups via classic statistical methods time from transplant to viremia was similar (HL 158 ± 77 days, LL 150 ± 76 days). Clinical factors were also similar with the exception of donor seropositivity (HL 87.5%, LL 70.4%, No CMV 49.6%, p = 0.025). HL CMV was significantly associated with graft loss (p < 0.0001) on Kaplan–Meier analysis; graft loss in the LL CMV group did not differ from the no CMV group (p = 0.96).To allow valid assessment of risk factors in the total study population (n = 209), models of time‐varying covariates were used, and Cox proportional hazards ratios were calculated. In this analysis, HL CMV was associated with a significantly increased risk of graft loss (HR 5.6, p = 0.0016). When investigating risk factors associated with HL CMV, donor seropositivity significantly increased risk (HR 8.85, 95% CI 1.13–71.43, p = 0.038). Pretransplant total bilirubin (HR 1.04, 95% CI 0.998–1.07, p = 0.06) trended toward significance. Recipient seronegativity, liver disease, clinical and allocation model for end‐stage liver disease (MELD), transplant surgery duration, age, sex, induction immunosuppression, and maintenance immunosuppression were not significantly associated with development of HL CMV.Conclusion: HL CMV after liver transplant is uncommon but is associated with a significantly increased risk of graft loss that is not present in those patients who develop LL CMV or do not develop CMV viremia. Given these negative graft effects, CMV stewardship interventions targeting recipients of CMV seropositive allografts are warranted. Future larger scale studies evaluating the potential role of other factors in risk stratification are needed. image


  • Letermovir conversion after valganciclovir treatment in cytomegalovirus high‐risk abdominal solid organ transplant recipients may promote development of cytomegalovirus‐specific cell mediated immunity

    by Margaret R Jorgenson, Hanna Kleiboeker, Neetika Garg, Sandesh Parajuli, Didier A Mandelbrot, Jon S Odorico, Christopher M Saddler, Jeannina A Smith

    Purpose: To evaluate the association of conversion from valganciclovir to letermovir on cytomegalovirus‐specific cellular immunity.Methods: Adult patients were included if they received a kidney or liver transplant between 8/1/2018‐12/31/20, developed symptomatic, high‐level CMV viremia and were converted to letermovir 480 mg daily as monotherapy after treatment with ganciclovir‐derivatives for a minimum of 4 weeks and had subsequent CMV cell‐mediated immunity (CMI) testing via ICS assay by flow cytometry (Viracor Eurofins T Cell Immunity Panel).Results: Seven patients met inclusion criteria; 87.5% were male and recipients of a kidney transplant. All patients were CMV high risk (D+/R‐). Mean time from transplant to CMV disease was 200 ± 91 days. Peak viral load (VL) during CMV treatment was 540,341 ± 391,211 IU/mL. Patients received a mean of 30 ± 24 weeks (range: 4‐78 weeks) of therapy with ganciclovir‐derivatives at induction doses prior to letermovir introduction. The median absolute lymphocyte count (ALC) at letermovir initiation was 400/μL (IQR 575) and the median VL was 51.6 (range: ND‐490) IU/mL. Most patients (n = 5/7, 71.4%) experienced an increase in VL 1 and/or 2 weeks after conversion to letermovir. All patients had positive CMI per ICS assay after conversion. Patients received a mean of 10.3 ± 6.9 weeks of letermovir prior to having a positive result. Median ALC at positivity was 900/μL. Immunosuppression was not further reduced from initiation of letermovir to demonstration of CMV CMI. No patient had progressive replication or breakthrough disease while maintained on letermovir and three patients (42.9%) underwent antiviral withdrawal without recurrence at the last follow‐up.Conclusion: In this case series of abdominal transplant recipients with severe or persistent CMV infection, patients developed CMV‐specific CMI after conversion to letermovir monotherapy. These data suggest that using letermovir in place of valganciclovir for secondary prophylaxis may address the lack of efficacy previously seen with this approach, as well as the issues that plague antiviral withdrawal with systematic monitoring. Future prospective studies are needed to evaluate this effect in a more controlled research environment with serial CMI testing to elucidate the optimal duration of letermovir when used in this way


  • The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients

    by Margaret R. Jorgenson, Jillian L. Descourouez, Neetika Garg, Sandesh Parajuli, Didier A. Mandelbrot, Jon S. Odorico, Christopher M. Saddler, Jeannina A. Smith

    Purpose: Persistent viral replication resulting in ongoing cytomegalovirus (CMV) viremia despite adequate therapy is difficult to manage and associated with negative outcomes. We report a case series of kidney transplant recipients receiving adjunctive letermovir in combination with valganciclovir for refractory CMV.Methods: Adult patients receiving a kidney or kidney‐pancreas transplant were included if they developed CMV viremia and initiated letermovir 480 mg daily as part of a dual therapy regimen with valganciclovir 900 mg twice daily between 1/9/2020 and 31/12/2020. Included patients received ≥90 days of valganciclovir and had a detectable viral load less than 1000 Iu/ml (log10 < 3) at the time of letermovir initiation. The primary objective was to evaluate the impact of adjunctive letermovir on viral clearance to negativity. We also evaluated effect of letermovir on tacrolimus levels.Results: Eight patients were included. Letermovir was added 223 ± 105 days after initiation of CMV treatment with ganciclovir derivatives. Median viral load at initiation was 139.7 (range: 73–355) IU/ml and did not clear or change significantly after 2, 4 and 12 weeks of adjunctive letermovir (132.5 [range: 34.5–513] IU/ml vs. 68.7 [range: 34.5–574] IU/ml vs. 78.3 [range: 34.5–347] IU/ml, p > 0.05). Tacrolimus was reduced by ∼30% in anticipation of a letermovir‐tacrolimus drug interaction. Despite this reduction, mean tacrolimus serum levels two weeks after adjunctive letermovir increased by 43% (5.6 ± 1.6 ng/ml vs 8.0 ± 4.6 ng/ml).Conclusion: In kidney and kidney‐pancreas recipients with refractory CMV, the use of adjunctive letermovir did not result in viral clearance. Additionally, despite a mean tacrolimus dose reduction of 30% at letermovir initiation, serum concentrations increased by over 40%. Further investigation into the optimal approach to refractory CMV is needed.


  • Open Access

    Fungal Infections in Liver Transplant Recipients

    by Michael Scolarici, Margaret Jorgenson, Christopher Saddler, Jeannina Smith

    Invasive fungal infections (IFIs) are one of the most feared complications associated with liver transplantation, with high rates of morbidity and mortality. We discuss the most common invasive fungal infections in the setting of liver transplant, including Candida, Aspergillus, and Cryptococcal infections, and some less frequent but devastating mold infections. Further, we evaluate the use of prophylaxis to prevent invasive fungal infection in this population as a promising mechanism to reduce risks to patients after liver transplant.


  • Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation

    by Margaret R. Jorgenson, Cynthia Wong, Jillian L. Descourouez, Christopher M. Saddler, Jeannina A. Smith, Didier A. Mandelbrot

    Purpose: In clinical practice, conversion from universal cytomegalovirus prophylaxis (CMV PPX) with valganciclovir (VGC) to targeted therapy (preemptive monitoring, PEM) is often pursued in the setting of leukopenia. It is unknown if this is an effective strategy.Methods: Adult patients receiving a kidney and/or pancreas transplant were included if converted from PPX to PEM between 9/1/19 and 3/1/20 due to leukopenia. A positive CMV viral load (VL) was defined as CMV PCR greater than the lower limit of quantification (LLOQ) based on local lab testing. A CMV VL of >500 IU/mL was chosen as the preemptive treatment (PET) threshold. Primary objective was to describe the impact of conversion on resolution of leukopenia. Secondary objectives were to assess PEM associated outcomes.Results: There were 49 patients converted from PPX to PEM due to leukopenia in the study period; 88% were KTRs and 96% received lymphocyte‐depleting induction; 84% were seropositive at transplant (R+) and 16% were high‐risk (D+/R−). Mean WBC at time of enrollment was 1.4 ± 0.4. After PEM conversion, WBC recovered to >3 in 87.8% of the population in a mean of 26.8 ± 24.5 days. Immunosuppression was modified in 96% of the population and GCSF was required in 46.9% of patients.CMV viremia occurred in 36.7% of the population; 78% were KTRs and 94% were R+. Time from PEM enrollment to PET was 64 ± 34 days. Median VL at first detection was 587 IU/mL, median peak was 1920 IU/mL. Five patients (27.8%) presented with symptoms consistent with CMV syndrome, none had end organ disease. Six patients (33%) presented with a VL <500 IU/mL at first detection, but all subsequently surpassed the threshold and required PET. Mean duration of PET was 25 ± 11 days. Mean change in WBC in response to PET was −0.4 ± 1.3. Immunosuppression required further adjustment in 61% of patients. There were no deaths or graft loss due to CMV at last follow‐up.Conclusion: In kidney and pancreas transplant recipients who undergo PEM conversion due to leukopenia, withholding of VGC can improve leukopenia, but other concomitant measures are necessary. This population should be considered fairly high risk, with a threshold of treatment of first quantifiable replication. Our findings suggest lack of harm from this approach but highlight the importance of close monitoring to prevent symptomatic replication. Larger studies with longer follow‐up are needed to better evaluate the impact of PEM conversion on late‐onset CMV and patient and graft outcomes.


  • Open Access

    Cytomegalovirus antiviral stewardship in the COVID‐19 Era: Increasing complexity of prophylaxis and treatment and potential mitigation strategies

    by Margaret R. Jorgenson, Jillian L. Descourouez, Cynthia Wong, Jill R. Strayer, Sandesh Parajuli, John P. Rice, Robert R. Redfield, Jeannina A. Smith, Didier A. Mandelbrot, Christopher M. Saddler

    Cytomegalovirus (CMV) infection is one of the most common and significant complications after solid organ transplant (SOT). Severe acute respiratory coronavirus 2 (SARS‐CoV‐2), which causes the novel betacoronavirus 2019 disease (COVID‐19), has become the first global pandemic in 100 years. The world's attention has turned to address this unanticipated development; however, the viral infection that has long plagued outcomes after solid organ transplantation still requires vigilance. With physical distancing as the key intervention to reduce the healthcare burden, and the unease related to healthcare contact within the transplant population given the associated morbidity and mortality of COVID‐19 in transplant recipients, providers have struggled to evaluate and streamline essential in‐person healthcare contact, including laboratory visits. Owing to this, the COVID‐19 pandemic has placed a significant strain on the delivery of CMV prophylaxis and treatment after solid organ transplantation. In this piece, we will describe issues our CMV antiviral stewardship service has encountered in the care of the transplant recipient with CMV during the this unprecedented time and share our expert opinion to approaches to providing optimal, evidenced based care during a pandemic associated with a seemingly unrelated viral infection.


  • The development and implementation of stewardship initiatives to optimize the prevention and treatment of cytomegalovirus infection in solid-organ transplant recipients

    by Margaret R. Jorgenson, Jillian L. Descourouez, Lucas T. Schulz, Kerry A. Goldrosen, John P. Rice, Robert R. Redfield, Christopher M. Saddler, Jeannina A. Smith, Didier A. Mandelbrot

    Classical stewardship efforts have targeted immunocompetent patients; however, appropriate use of antimicrobials in the immunocompromised host has become a target of interest. Cytomegalovirus (CMV) infection is one of the most common and significant complications after solid-organ transplant (SOT). The treatment of CMV requires a dual approach of antiviral drug therapy and reduction of immunosuppression for optimal outcomes. This dual approach to CMV management increases complexity and requires individualization of therapy to balance antiviral efficacy with the risk of allograft rejection. In this review, we focus on the development and implementation of CMV stewardship initiatives, as a component of antimicrobial stewardship in the immunocompromised host, to optimize the management of prevention and treatment of CMV in SOT recipients. These initiatives have the potential not only to improve judicious use of antivirals and prevent resistance but also to improve patient and graft survival given the interconnection between CMV infection and allograft function.